Core Viewpoint - A class action has been filed against CTO Realty Growth, Inc. for allegedly misleading investors about its financial health and sustainability of dividends during the specified period [1][2]. Allegations - The complaint states that CTO Realty Growth, Inc. did not disclose that its dividends were less sustainable than claimed, used deceptive practices to inflate its Adjusted Funds from Operations (AFFO), and overstated its business and financial prospects [2]. - Wolfpack Research's report accused CTO of not generating sufficient cash to cover its recurring capital expenditures and dividends since its conversion to a REIT in 2021, relying on a 70% increase in shares outstanding to cover a $38 million dividend shortfall from 2021 to 2024, and employing a manipulative definition of AFFO [3]. Financial Condition - The report highlighted that CTO had only $8.4 million in cash while facing quarterly dividends of $14 million and average recurring capital expenditures of $5.7 million, along with an additional $12 million in planned capital expenditures [3].

Core Viewpoint - Spectrum Pharmaceuticals, Inc. is facing a class action lawsuit alleging false or misleading statements regarding its clinical trial for the drug poziotinib, which is intended for lung cancer treatment [2]. Group 1: Company Overview - Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies [1]. Group 2: Legal Proceedings - The class action lawsuit pertains to the Pinnacle Study, a clinical trial involving the drug poziotinib [2]. - The Lead Plaintiff appointment process has reopened, allowing shareholders who purchased shares between March 17, 2022, and September 22, 2022, to file their papers by September 24, 2025 [3]. Group 3: Shareholder Information - Shareholders do not need to participate in the case to be eligible for recovery [3]. - Robbins LLP operates on a contingency fee basis, meaning shareholders pay no fees or expenses [4].

Core Viewpoint - A class action lawsuit has been filed against SelectQuote, Inc. for allegedly violating the False Claims Act by directing Medicare beneficiaries to plans that compensated the company rather than providing unbiased comparisons [1][2][3] Allegations - SelectQuote is accused of failing to disclose that it directed Medicare beneficiaries to plans based on compensation rather than quality [2] - The company allegedly did not provide unbiased comparison shopping for Medicare Advantage insurance plans [2] - SelectQuote is claimed to have received illegal kickbacks to steer beneficiaries towards certain insurers, limiting enrollment in competitors' plans [2] - The company is said to have violated applicable laws and regulations, making it vulnerable to regulatory and legal sanctions [2] - The U.S. Department of Justice filed a complaint alleging SelectQuote received "tens of millions of dollars" in illegal kickbacks from 2016 to 2021 [3] Impact on Stock Price - Following the DOJ's allegations, SelectQuote's stock price fell by $0.61, or 19.2%, closing at $2.56 per share on May 1, 2025 [3]

Core Viewpoint - A class action lawsuit has been filed against CTO Realty Growth, Inc. for allegedly misleading investors about its financial health and sustainability of dividends during the specified period [1][2]. Allegations - The lawsuit claims that CTO Realty Growth misrepresented the sustainability of its dividends, which were less stable than communicated to investors [2]. - It is alleged that the company employed deceptive practices to inflate its Adjusted Funds from Operations (AFFO) and overstated the profitability of its Ashford Lane property [2]. - The complaint highlights that CTO's business and financial prospects were overstated, leading to investor misinformation [2]. Financial Concerns - A report by Wolfpack Research accused CTO of failing to generate sufficient cash to cover its recurring capital expenditures and dividends since its conversion to a REIT in 2021 [3]. - The report noted that CTO increased its shares outstanding by 70% since December 2022 to cover a $38 million dividend shortfall from 2021 to 2024 [3]. - CTO reportedly has only $8.4 million in cash while facing quarterly dividends of $14 million and average recurring capital expenditures of $5.7 million per quarter, along with an additional $12 million in planned capital expenditures [3]. Stock Impact - Following the publication of the report, CTO's stock price fell by over 5% [3]. Class Action Participation - Shareholders interested in participating as lead plaintiffs in the class action must submit their papers by October 7, 2025 [4]. - Shareholders can remain absent class members if they choose not to participate in the case [4]. Company Background - Robbins LLP is noted as a leader in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance [5].

Core Viewpoint - A class action lawsuit has been filed against Altimmune, Inc. for allegedly misleading investors regarding the results of its IMPACT Phase 2b MASH trial, leading to a significant drop in stock price [2]. Group 1: Company Overview - Altimmune, Inc. is a clinical stage biopharmaceutical company focused on developing treatments for obesity, metabolic, and liver diseases [1]. Group 2: Allegations and Impact - The lawsuit claims that during the class period, Altimmune's management made positive statements about the expected results of the MASH trial [2]. - On June 26, 2025, Altimmune announced that it failed to achieve statistical significance in the trial due to a higher-than-expected placebo response, resulting in a stock price drop from $7.71 to $3.61, a decline of over 53% in one day [2]. Group 3: Legal Proceedings - Shareholders interested in serving as lead plaintiffs must submit their papers by October 6, 2025, and can choose to remain absent class members if they do not wish to participate [3].

Core Viewpoint - A class action lawsuit has been filed against Lineage, Inc. for allegedly misleading investors during its 2024 IPO, with claims that the company failed to disclose significant operational challenges and declining market conditions [1][2]. Group 1: Allegations Against Lineage, Inc. - The registration statement for the IPO filed on June 26, 2024, was claimed to be false and misleading, failing to disclose that Lineage was experiencing a decline in customer demand due to increased cold-storage supply and destocking of excess inventory from the COVID-19 pandemic [2]. - Lineage reportedly implemented unsustainable price increases prior to the IPO, which could not be maintained in the face of weakening demand [2]. - The company was unable to counteract adverse trends through operational efficiencies or competitive advantages, leading to stagnant or falling revenue, occupancy rates, and rent prices, contrary to the representations made in the registration statement [2]. Group 2: Stock Performance - Since the IPO, Lineage's stock price has dropped to approximately $40 per share, remaining significantly below the IPO price at the time of the complaint [3]. Group 3: Class Action Participation - Shareholders interested in serving as lead plaintiffs in the class action must submit their papers by September 30, 2025, although participation is not required to be eligible for recovery [4].

Group 1 - A class action has been filed on behalf of investors who purchased Sable Offshore Corp. (NYSE: SOC) securities between May 19, 2025, and June 3, 2025, and/or traceable to the Company's May 21, 2025 secondary public offering [1] - The allegations state that Sable Offshore Corp. misled investors by claiming that oil production had restarted off the coast of California when it had not [2] - The complaint indicates that investors suffered damage when the true details regarding oil production were revealed [2] Group 2 - Shareholders interested in serving as lead plaintiff must submit their papers by September 26, 2025 [3] - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [3] - Robbins LLP operates on a contingency fee basis, meaning shareholders pay no fees or expenses [4]

Core Viewpoint - A class action lawsuit has been filed against Alto Neuroscience, Inc. for allegedly misleading investors regarding the effectiveness of its drug candidate ALTO-100 during its IPO and subsequent period [1][2]. Company Overview - Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company based in the U.S. with a product pipeline that includes ALTO-100, which was in a Phase 2b clinical trial for treating major depressive disorder (MDD) at the time of its IPO [1]. Allegations - The lawsuit claims that the Offering Documents related to the IPO were negligently prepared and that the company failed to disclose critical information about ALTO-100's effectiveness, overstating its clinical, regulatory, and commercial prospects [2]. - Specifically, it is alleged that ALTO-100 was less effective in treating MDD than represented, leading to an overestimation of Alto's business and financial prospects [2]. Stock Performance - Following the announcement on October 22, 2024, that ALTO-100 did not meet its primary endpoint in the Phase 2b trial, Alto's stock price plummeted by $10.17 per share, a decrease of 69.99%, closing at $4.36 per share on October 23, 2024 [3]. Legal Proceedings - Shareholders interested in participating in the class action have until September 19, 2025, to seek lead plaintiff status, which allows them to represent other class members in the litigation [4].

Core Viewpoint - Neogen Corporation is facing a class action lawsuit due to allegations of misleading investors regarding its integration with 3M Company, which has negatively impacted its financial health [2][3]. Financial Performance - On January 10, 2025, Neogen reported a GAAP net income that was significantly negative, primarily due to a $461 million non-cash goodwill impairment charge related to the 3M acquisition [3]. - Neogen cut its fiscal year 2025 revenue and EBITDA guidance following the negative financial disclosures [3]. - On April 9, 2025, Neogen announced a quarterly revenue decline of 3.4% to $221 million, attributing part of this decline to integration issues [4]. - The company expected capital expenditures to be $100 million due to lowered adjusted EBITDA and a pull-forward of integration-related capital expenditures into FY25 [4]. - On June 4, 2025, Neogen projected an EBITDA margin in the high teens, a significant drop from the previous quarter's margin of 22% [5]. Stock Performance - Following the January 10, 2025 announcement, Neogen's stock price fell by 5% to close at $12.36 per share [3]. - After the April 9, 2025 announcement, the stock price plummeted by 28% [4]. - By June 4, 2025, the stock price had further declined by 17%, closing at $4.96 per share, marking a total drop of $18.88 per share or 79% from its August 15, 2023 high of $23.84 per share, erasing over $4 billion in market capitalization [5].

Group 1 - A class action has been filed on behalf of investors who purchased Sable Offshore Corp. (NYSE: SOC) securities between May 19, 2025, and June 3, 2025, related to the company's secondary public offering on May 21, 2025 [1][2] - The allegations state that Sable Offshore Corp. misled investors by claiming it had restarted oil production off the coast of California when it had not, leading to investor losses when the truth was revealed [2] - Shareholders interested in serving as lead plaintiff must submit their papers by September 26, 2025, and can remain absent class members if they choose not to participate [3] Group 2 - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses for representation [4]